Diagnosis, Classification and the 2025 ASAS–SPARTAN Revised Axial Criteria
Use peripheral and axial classification in their intended populations, with explicit criteria versions and a separate clinical diagnostic judgment.
On this page
Classification is a research decision; diagnosis is a clinical judgment
Classification criteria assemble sufficiently comparable participants for research. Clinical diagnosis asks what best explains an individual patient’s findings and what must be done next. The two processes share evidence but have different purposes and tolerances for error. A criteria-positive result does not remove competing diagnoses, and a criteria-negative result does not automatically exclude clinically credible disease.
This matters especially in peripheral SpA, where the entry manifestation may itself be uncertain. Tenderness at a heel is not automatically inflammatory enthesitis. A reported swollen finger is not necessarily dactylitis. Classification performed before confirming the nature of the manifestation can convert a weak premise into an apparently authoritative conclusion.
The 2011 peripheral framework
The ASAS peripheral criteria start with arthritis, enthesitis or dactylitis. Classification then uses either at least one of psoriasis, IBD, preceding infection, HLA-B27, uveitis or sacroiliitis on imaging; or at least two of arthritis, enthesitis, dactylitis, previous inflammatory back pain or family history of SpA. Apply the published definitions rather than counting loosely related symptoms. [1]
The framework was developed in newly referred patients with peripheral manifestations, generally beginning before age 45. That derivation context is not a bedside rule that peripheral SpA becomes impossible after a birthday. It is a reason to scrutinize transportability, competing diagnoses and the meaning of test performance in a different clinical population.
The historical 2009 axial framework
The 2009 axial criteria address chronic back pain beginning before age 45. They allow classification through sacroiliitis on imaging plus a SpA feature, or through HLA-B27 plus additional SpA features. [2] Those entry conditions are central. Applying an axial algorithm to a person without an axial presentation does not establish the cause of an ankle effusion.
Likewise, “non-radiographic” is not a synonym for undifferentiated peripheral disease. It refers to an axial classification context. A patient whose historical uSpA diagnosis was principally axial should be reassessed within the appropriate axial pathway, while the current peripheral manifestations are recorded in parallel.
What changed in the 2025 ASAS–SPARTAN work
The revised axial criteria were presented in ACR Convergence 2025 abstract 0854 on October 27, 2025. The CLASSIC development and validation work pursued higher specificity and reported revised weighted criteria with greater emphasis on imaging. In the validation results reported in the abstract, sensitivity was 79.5% and specificity 90.4%. [3] These are study-level performance estimates, not the probability that a particular patient has or lacks axSpA.
Publication status on October 6, 2026: the original development evidence cited here is a congress abstract. A 2026 peer-reviewed letter evaluates the proposed criteria in an acute anterior uveitis cohort; that is additional validation work, not the original full criteria-development report. [4] The criteria name remains 2025 ASAS–SPARTAN revised axial criteria. Later analyses do not change that version label.
The central clinical consequence is to separate a more specific research gate from the full diagnostic assessment. Stricter classification can change who enters a study without determining that excluded patients have no inflammatory disease. The converse remains equally important: imaging must be read in context, not accepted uncritically because a revised framework emphasizes it.
Imaging specificity is a clinical problem too
Sacroiliac bone-marrow edema is not unique to axSpA. A primary MRI study found findings meeting an ASAS imaging definition in some healthy participants and people exposed to mechanical or postpartum stress. [5] A radiology phrase must therefore be interpreted alongside lesion distribution, structural findings, image quality, symptoms and competing explanations. Do not transform “edema present” directly into “inflammatory axial disease established.”
When an imaging report and clinical picture disagree, obtain clarification or expert review of the actual study. Repeating scans indiscriminately is less useful than identifying the unresolved question: artifact, mechanical stress, infection, structural lesion interpretation, or insufficiently characterized symptoms. A negative scan also has to be interpreted in its temporal and treatment context.
How to document a criteria result responsibly
| Field | What to record |
|---|---|
| Clinical diagnosis | Working disease explanation, confidence, phenotype and alternatives |
| Classification framework | Exact name and year; peripheral or axial population |
| Entry condition | How the required manifestation or symptom history was established |
| Supporting items | Confirmed evidence, its source and date; uncertain items kept separate |
| Imaging | Modality, site, date, relevant interpretation and review where needed |
| Meaning | Research eligibility or descriptive classification, without substituting for diagnosis |
| Reassessment | What new finding would change the judgment or route |
Common errors and their consequences
Counting an uncertain manifestation as certain: an equivocal skin rash, generic family “arthritis,” or undocumented red eye should not silently become a confirmed item. Clarify the source. Double-counting clinical impressions: several descriptions of the same uncertain symptom do not create independent evidence. Using treatment response as proof: analgesic and anti-inflammatory responses occur in multiple conditions.
Using classification to deny the differential: criteria-positive SpA does not protect the patient from infection, gout or a second inflammatory disease. Using a negative result to end evaluation: a framework optimized for research specificity can miss some clinically diagnosed disease. Applying the wrong population: axial, peripheral and PsA criteria should not be mixed into an improvised score.
Version control for educational tools
An educational classification tool should state exactly which criteria it implements, retain the original entry requirements and display publication status when discussing new versions. Its output should explain the limited meaning of a classification result. Updating a heading without auditing the questions, definitions and branching logic would be misleading.
This chapter links directly to the source reports rather than presenting an unverified reproduction of the new weighted algorithm. For bedside decisions, use the full clinical assessment. For research enrollment, use the protocol-specified version and the original definitions, not a blended recollection of several generations of criteria.
Evidence in context
Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.
Scrollable evidence table
| Source | Population and phenotype | Design and status | Applicability | Clinical implication | Important limitation | Last checked |
|---|---|---|---|---|---|---|
| 2011 peripheral criteria [1] | Peripheral entry manifestations | Development/validation; peer-reviewed | Peripheral classification | Keep the correct entry phenotype | Not diagnostic criteria for an unselected patient | 2026-10-06 |
| 2009 axial criteria [2] | Chronic back pain with young onset | Development/validation; peer-reviewed | Axial classification | Historical version must remain identified | Not transferable wholesale to peripheral disease | 2026-10-06 |
| 2025 ASAS–SPARTAN [3] | CLASSIC axial referral cohort | Development/validation; congress abstract | Revised axial classification | Higher-specificity research framework | Original full development paper not established here | 2026-10-06 |
| Uveitis validation [4] | Acute anterior uveitis cohort | Published letter, July 2026 | Selected external axial context | Shows ongoing validation work | Not the original criteria-development report | 2026-10-06 |
| MRI comparator study [5] | Healthy, axial disease, back-pain and stress-exposed groups | Cross-sectional; peer-reviewed | Axial imaging interpretation | Edema alone is not disease-specific | Selected groups; small postpartum subgroup | 2026-10-06 |
Sources
- Rudwaleit et al. ASAS peripheral classification criteria (2011)
- Rudwaleit et al. ASAS axial criteria: validation and final selection (2009)
- Maksymowych et al. 2025 ASAS–SPARTAN revised axial criteria: ACR abstract 0854
- Rai et al. Performance of proposed ASAS/SPARTAN criteria in uveitis: letter (2026)
- de Winter et al. Sacroiliac MRI in healthy individuals, runners and postpartum back pain (2018)